Study to see if riboflavin reduces neuronal damage in patients with acute ischemic stroke

Phase 1

• Conditions: Acute ischemic stroke; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2014-003123-22-ES
• Lead Sponsor: José Castillo Sanchez

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-11-05
• Last Update Posted: 13 March 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

- Patients older than 18 years, both men and women.
- Patient or legal representative able to understand and sign the informed consent.
- Patients with suspected stroke within 3 hours of onset.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 35
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

- Women of childbearing age, with potential for pregnancy or breastfeeding.
- Patients with a score ? 2 point 1a in the NIHSS scale.
- Scale pre-stroke modified Rankin ? 2.
- Inability to prior testing image needed for the study.
- previous disorders that may interfere with the interpretation of neurological scales.
- Treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin, erythromycin, tirotricina, tetraciclines and carbomycin, at the time of inclusion.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified